2013
DOI: 10.1177/1358863x13503695
|View full text |Cite
|
Sign up to set email alerts
|

n-3 Polyunsaturated fatty acids supplementation in peripheral artery disease: the OMEGA-PAD trial

Abstract: Despite current consensus guidelines recommending intensive cardiovascular risk factor management for peripheral artery disease (PAD), patients suffering from PAD continue to experience significant morbidity and mortality. This excess morbid burden is at least partially related to impaired vascular function and systemic inflammation. Interventions bridging this gap are critical. Dietary supplementation of n-3 polyunsaturated fatty acids (n-3 PUFA) has been shown to improve endothelial function and reduce infla… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
28
0

Year Published

2014
2014
2020
2020

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 27 publications
(29 citation statements)
references
References 99 publications
1
28
0
Order By: Relevance
“…9 We previously demonstrated that the O3I was inversely associated with inflammatory status in patients with PAD. 10 Our data also demonstrate that supplementation with n -3 PUFA leads to decreased adhesion of monocytes to the endothelial monolayer in vitro . 11 …”
Section: Introductionsupporting
confidence: 64%
See 1 more Smart Citation
“…9 We previously demonstrated that the O3I was inversely associated with inflammatory status in patients with PAD. 10 Our data also demonstrate that supplementation with n -3 PUFA leads to decreased adhesion of monocytes to the endothelial monolayer in vitro . 11 …”
Section: Introductionsupporting
confidence: 64%
“…10 The investigator-initiated protocol was approved by the Committee on Human Research at the University of California, San Francisco (UCSF) and all patients provided informed consent. Patients referred to the outpatient vascular surgery clinic of the San Francisco Veterans Affairs Medical Center (SF VAMC) for evaluation of PAD were screened for the study.…”
Section: Methodsmentioning
confidence: 99%
“…32 Importantly, studies have shown that increasing n-3 PUFA intake, especially EPA and DHA (the most biologically active in terms of inflammation resolution), can help balance high n-6/n3 ratios. 32,33 Thus, when indicated, EPA and DHA supplementation may help reduce the chronic inflammation associated with CVLUs.…”
Section: Discussionmentioning
confidence: 99%
“…We included baseline data from patients enrolled into the OMEGA-PAD trial (NCT01310270) and the OMEGA-PAD Cohort. 13 Subjects were enrolled if they had at least one of the following inclusion criteria: intermittent claudication associated with an ankle-brachial index (ABI) < 0.9, toe pressures < 70 mm Hg, or imaging confirming >50% stenosis in the lower extremity arteries. Intermittent claudication was diagnosed based on fatigue, discomfort, or pain that occurs in specific limb muscle groups during effort due to exercise-induced ischemia.…”
Section: Methodsmentioning
confidence: 99%